Spermosens Expands IP Portfolio with Israeli Patent
Spermosens strengthens its global intellectual property with a new patent in Israel, enhancing its JUNO-Checked technology's market reach.
Sammanfattning
Spermosens has secured a patent in Israel for its JUNO-Checked technology, further solidifying its global IP presence in fertility diagnostics.
Spermosens AB, a leader in fertility diagnostics, has announced the expansion of its intellectual property portfolio with a newly granted patent in Israel. This development marks a significant milestone for the company, which already holds patents in major markets including Europe, the United States, and Japan. The patent covers both the method and system underlying Spermosens' proprietary JUNO-Checked technology.
CEO Tore Duvold expressed the strategic importance of this patent, emphasizing Israel's robust life science sector and advanced fertility care. Duvold stated, 'The granted patent in Israel is an important step for our global IP coverage. JUNO Checked is unique in its ability to directly measure sperm-egg interaction, something conventional tests cannot assess.'
JUNO-Checked is a groundbreaking diagnostic tool that assesses the ability of sperm to bind to the JUNO receptor on the egg, a critical step in fertilization that conventional semen analyses cannot evaluate. By replicating this process in vitro, JUNO-Checked offers a functional measurement of sperm-egg binding, providing valuable insights into male fertility.
Spermosens' commitment to innovation and scientific excellence positions it at the forefront of fertility diagnostics. The company's strategic collaborations with leading research institutions aim to deliver transformative solutions to the global market.
For investors, the expansion of Spermosens' IP portfolio into Israel is a promising development. It not only secures long-term exclusivity for its technology but also opens doors to a strategically important market. Given these advancements and the company's robust approach to expanding its market reach, investors may consider holding their positions in Spermosens as the company continues to solidify its presence in the fertility diagnostics industry.
Källa
Sammanfattning
Spermosens har fått ett patent i Israel som stärker deras immateriella rättighetsportfölj, vilken redan inkluderar patent i flera viktiga marknader som Europa, USA, Japan och andra länder. Skyddet täcker både metoden och systemet bakom deras JUNO-Checked teknologi, vilket ger långsiktig exklusivitet för deras metod att bedöma viktig spermiefunktion. VD Tore Duvold kommenterar att patentet i Israel är ett viktigt steg för deras globala IP-täckning, särskilt eftersom Israel är en strategiskt viktig marknad med en stark livsvetenskapssektor. JUNO-Checked är en diagnostisk teknologi som bedömer spermiernas förmåga att binda till JUNO-receptorn på ägget, en viktig del av befruktningen som inte kan bedömas med konventionella tester. Spermosens är ett bioteknikföretag i Sverige som fokuserar på att förbättra fertilitetsdiagnostik och utvecklar teknologier för att förbättra fertilitetsresultat. Deras produkt JUNO-Checked erbjuder en ny metod för att mäta spermie-äggbindning, vilket stödjer bättre kliniska beslut och individuella behandlingsstrategier. Företaget samarbetar med ledande forskningsinstitutioner och deras aktier är noterade på Spotlight Stock Market.
